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Baby-hamster kidney cells were treated with unspecific and phosphatidylinositol-specific phospholipase C (PI-PLC) prior to infection with herpes 
simplex virus type 1 or 2. Subsequent to PI-PLC treatment, a 30% reduction of infectivity and receptor binding was observed for type 1 virus, 
while type 2 was unaffected. Treating the cells with unspecific phospholipase C did not affect subsequent infection with either virus. Treatment 
of the virus particles with the unspecific phospholipase reduced its infectivity, probably due to loss of the viral envelope. PI-PLC treatment of 
virus particles did not have any such effect on virus infectivity. 
Herpes simplex virus type I; Receptor; Phosphatidylinositol-anchoring; Phosphatidylinositol-specific phospholipase C
1. INTRODUCTION 
Anchoring of cell surface proteins to the plasma 
membrane through covalent binding to inositol- 
containing phospholipids in the membrane has been 
demonstrated for a number of proteins (reviewed in 
[l]). Among these are heparan sulphate proteoglycans, 
which in their plasma membrane form can be 
phosphatidylinositol (PI)-anchored [2,3]. We have 
previously demonstrated that polycations such as 
neomycin and polylysine inhibit binding of herpes 
simplex virus type I (HSV-1) to its cellular receptor by 
interference with receptor function [4,5]. Since 
neomycin is known to bind strongly to 
phosphoinositides, as shown by nuclear magnetic 
resonance studies [6], and polylysine interferes with the 
known PI-anchored membrane protein 
acetylcholinesterase [7], PI-anchoring of the HSV-1 
receptor was a possible explanation of our results. 
Moreover, the finding that the HSV-1 receptor is most 
probably a heparan sulphate-containing cell surface 
protein [8] made this possibility even more likely. In this 
paper we demonstrate that the HSV-1 receptor is at 
least partially anchored to the plasma membrane via a 
PI-anchor in baby-hamster kidney cells. 
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Baby-hamster kidney (BHK) 21 clone 13 cells were grown until con- 
fluence in 32 mm plastic dishes in EMEM supplemented with 10% 
newborn calf serum. The virus strains used were HSV-1 strain 
17syn + and HSV-2 strain HG52. [35S]Methionine-labelled virus was 
prepared as described elsewhere [5]. ‘2P-Labelling of virions was per- 
formed similarly, with 50 &i label present per ml medium as the virus 
was propagated in BHK cells. Virions were harvested and purified as 
described [9]. [‘HlInositol-labelling of BHK cell was performed by 
growing the cells for 48 h in the presence of medium supplemented 
with 10 &i/ml [3H]inositol. Labelled medium was removed and cells 
were washed extensively with phosphate-buffered saline before PLC- 
treatment. 32P-Labelling was performed similarly, except that 5 pCi 
[32P]Pi was present for 24 h, and removed from the medium before 
experiments were started. Before PLC-treatment, ‘*P-labelled cells 
were disrupted by sonication in order to make a major part of the 
labelled phospholipids available to the enzyme. In plaque assays and 
virus binding experiments, cells were intact so that infection could be 
assayed. 
Abbreviations: PI, phosphatidylinositol; PC, phosphatidylcholine; 
PLC, phospholipase C; PI-PLC, phosphatidylinositol-specific 
2.3. PLC treatment of cells and viruses 
Confluent BHK cells were treated with various concentrations of 
phospholipase C; HSV-1, herpes simplex virus type 1; HSV-2, herpes 
simplex virus type 2; BHK cells, baby-hamster kidney cells 
PLC for 1 h at 37°C before the enzyme-containing medium was 
carefully removed. In virus titration assays, approximately 50 plaque- 
2. MATERIALS AND METHODS 
2.1. Materials 
Eagle’s minimum essential medium (EMEM) and newborn calf 
serum were purchased from Flow Laboratories (Irvine, Ayrshire, 
UK). Cell culture dishes were purchased from Nunc (Roskilde, Den- 
mark). [32P]Pi (10 mCi/ml, carrier-free) and [3H]inositol (1 mCi/ml) 
were from Amersham International (Amersham, Bucks., UK). 
Unspecific phospholipase C (PLC) was from Sigma Chemical Co. (St. 
Louis, MO, USA) and the PI-specific PLC (PI-PLC) from Funakoshi 
Pharmaceutical Co. (Tokyo, Japan). For preliminary experiments, 
the PI-PLC used were the generous gifts from Dr H. Ikezawa 
(Nagoya City University, Japan) and Dr Martin Low (Columbia 
University, New York, USA). Thin layer chromatography plates and 
chemicals were obtained from Merck (Darmstadt, Germany). 
2.2. Cells and virus 
Published by Elsevier Science Publishers B. K (Biomedical Division) 
00145793/90/$3.50 0 1990 Federation of European Biochemical Societies 253 
Volume 277, number 1,2 FEBS LETTERS December 1990 
forming units of virus was added per dish. After a 1 h adsorption 
period, medium was changed and incubations continued for 48 h, at 
which time plaque formation was recorded. When [32S]methionine- 
labelled virus was added, adsorption was assayed at 4°C. After 1 h in- 
cubation, cells were washed extensively with phosphate-buffered 
saline, and bound radioactivity was measured. Unspecific binding 
was subtracted and defined as the binding of radiolabel obtained in 
the presence of 2000 times excess of cold virus. Experiments were per- 
formed so that specifically bound radioactivity was in the range of 
5OOO-10 00 cpm per dish. 
When the virus was PLC-treated, stock solutions of HSV-1 or 
HSV-2 were treated with various concentrations of PLC for 1 h at 
37°C. The virus solution was then diluted by 10” in medium before it 
was added to the cells in plaque assays. Cells were thus exposed to 
PLC-concentrations (for the 1 h adsorption period) far below the ones 
which were effective on cells. All experiments were performed with 
triplicate incubations at each point. Each experiment was repeated 4 
times, yielding similar results. 
2.4. Phospholipid extruction and separation 
A modification of the extraction procedure described by Bligh and 
Dyer [lo] was used, as previously described [l I]. Individual 
phospholipids were separated in a chloroform/methanol/40% 
methylamine/water (60:36:5:5 v/v) solvent system as described by de 
Chaffoy de Courcelles et al. [ 12). Radioiabelled phospholip~ds were 
detected by autoradiography. 
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3. RESULTS 
3.1, Treff~rne~r by unspecific phosphol~~~se C 
First, the effect of treating either host cells or virus 
with unspecific PLC prior to infection was assayed. 
Generally, the acidic phospholipids such as 
phosphatidyl serine, phosphatidylinositol and its 
phosphorylated derivatives were unaffected by the 
unspecific PLCs tested, while the remaining major 
phospholipids were degraded by these enzymes (data 
not shown). Fig. IA and C shows the enzymatic 
degradation of phosphatidyl choline (PC) and 
phosphatidylinositol (PI) in sonicated host cells (A) and 
virions (C). Both in the cells and the virions, the 
unspecific PLC degraded PC at moderate PLC concen- 
trations, while PI was unaffected. 
Next, the effect of PLC treatment on HSV-1 and 
HSV-2 infection was assayed. As shown in Fig. lB, 
unspecific PLC treatment of intact cells, had no signifi- 
cant effect on subsequent infection by either HSV-I or 
HSV-2 in the range of PLC concentrations tested. In- 
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Fig. 1, Effect of unspecific PLC treatment on phospholipid hydrolysis and HSV infectivity. Host cells (A and B) or virions (C and D) were treated 
with the indicated amounts of PLC for 1 h at 37°C before subsequent extraction of 32P-labelled phospholipids (A and C) or HSV-l/HSV-2 
infection of the cells (B and D). The hydroiysis of PC (open squares) and PI (closed squares) are indicated (A and C) as percentage of cpm obtained 
in the absence of enzyme. Panels B and D show plaque numbers after infection with HSV-1 (closed circles) or HSV-2 (open circles) as percentage 
of the plaque numbers obtained in the absence of enzyme. Data are means of triplicate determinations. 
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Fig. 2. Effect of PI-PLC treatment of host cells on phospholipid 
hydrolysis and HSV infectivity. The upper panel shows hydrolysis of 
[32P]PC (open squares) and [‘*PIP1 (closed squares). The lower panel 
shows the plaque numbers after infection with HSV-I (closed circles) 
or HSV-2 (open circles). Data presentation and experimental 
conditions were as described in the legend to Fig. 1. 
fection was assayed as plaque numbers, i.e. complete 
infection cycles. Unspecific PLC-treatment of HSV-1 
and HSV-2 (Fig. 1D) did, on the other hand, reduce in- 
fectivity at concentrations corresponding to those 
which degraded PC. 
3.2. Treatment by PI-specific PLC 
PI-PLC treatment of virus particles did not affect 
subsequent infection of BHK cells at doses up to 5 units 
PLC per ml (data not shown). PI-PLC did selectively 
degrade PI both of virions (not shown) and cells (Fig. 2, 
upper panel). The data presented in Fig. 2 (lower panel) 
also show that PI-PLC treatment of cells inhibited 
subsequent infection of HSV-1, while HSV-2 infection 
was unaffected. The concentrations necessary for full 
effect were, however, higher than those yielding max- 
imal degradation of PI (Fig. 2, upper and lower panels). 
PI-PLC treatment of BHK cells was also performed 
in experiments where subsequent binding of radiolabell- 
ed HSV-1 or HSV-2 was assayed (Fig. 3). While 2.5 U 
PI-PLC inhibited binding of [35SJHSV-l by approx- 
imately 30% [35S]HSV-2 binding was not significantly 
affected. 
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Fig. 3. Effect of PI-PLC treatment of BHK cells on subsequent 
binding of 35S-IabeIIed HSV-1 and HSV-2. Binding was assayed at 
4°C. Control binding was the specific radioactivity obtained in the 
absence of enzyme. Data are means +SD for triplicate 
determinations. 
4. DISCUSSION 
PI-PLC treatment of intact cell is considered to 
specifically release PI-containing compounds, and 
release of proteins after enzyme treatment hus being 
evidence for PI-anchoring [l]. A number of proteins 
have been shown to be attached to the membrane in this 
way. Among these are heparan sulphate-containing 
proteoglycans, which in their plasma membrane form 
have been shown to be at least partially PI-linked; in 
ovarian granulosa cells of rats, approximately 25% of 
the plasma membrane heparan sulphate proteoglycans 
were found to be PI-anchored [ 131. Based on the report 
that heparan sulphate is an essential part of the HSV 
receptor [8], this raised the possibility of PI-anchoring 
of the HSV receptor. The observations that PI-PLC 
treatment of BHK cells reduced subsequent HSV-1 in- 
fection by approximately 30% in plaque assays (Fig. 2) 
as well as in binding assays (Fig. 3), both support this. 
The specificity of the observed enzymatic degradation is 
confirmed both by testing degradation of individual 
phospholipids (Fig. 1A and C, Fig. 2), and by the lack 
of effect of unspecific PLC on infection (Fig. 1B). The 
finding that the unspecific PLC affected the infectivity 
of both HSV-1 and HSV-2 (Fig. 1D) was not unex- 
pected, as enveloped viruses all depend on their intact 
membranes for infectivity. 
The finding that PI-PLC treatment only partially 
reduced binding and infection of HSV-1 could be ex- 
plained in various ways. Since the observed 30% reduc- 
tion in binding of HSV-I coincides remarkably well 
with the 2%30% PI-anchoring of plasma membrane 
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heparan sulphate proteoglycans observed in other cells, 
our observations could be caused by binding of the 
virus to all heparan sulphate present on the cell surface, 
whether it was PI-linked or not, while only the PI- 
linked fraction was degraded. 
The limited effect of the PI-PLC in our assays could 
just as well be caused by inefficiency of the PI-PLC in 
degrading the anchors, as has been shown in other 
systems, such as for the Thy-l antigen [14] and the 
human erythrocyte acetyicholinesterase [15]. Both of 
these are PI-anchored proteins, but the anchors are in 
some way less available to the enzyme. 
The recent report that HSV-1 binding to the 
fibroblast growth factor receptor could account for 
70% of HSV-1 binding in certain cells 1161, could be an 
alternative explanation of our finding of only 30% 
reduction of binding after PI-PLC treatment. Alter- 
natively, the PI-anchoring may not be of the receptor 
molecule, but of a protein with some ‘supportive’ func- 
tion in the adsorption process. 
The finding that HSV-2 receptor binding was unaf- 
fected by PI-PLC treatment was interesting. Previous 
results indicated that in our cell system, HSV-1 and 
HSV-2 bind to separate receptors [17]. The results 
presented in this paper support these findings. 
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